Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419744 · ClinicalTrials.gov registry record · Phase 3
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT00419744: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
NCT00419744 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that has completed, run by AstraZeneca. The registered enrollment target is 1,200 participants, below the 1,740-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419744, a Phase 3 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
Primary Outcome
Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.
Conditions Studied
Interventions
- DRUG Budesonide/formoterol (SYMBICORT) pMDI
- DRUG Formoterol Turbuhaler
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Foothill Ranch
- Research Site - Fullerton
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Site - Los Banos
- Research Site - Mission Viejo
- Research Site - Pismo Beach
- Research Site - Rancho Cordova
- Research Site - Rancho Mirage
- Research Site - Riverside
- Research Site - Rolling Hills Estates
- Research Site - Sacramento
- Research Site - San Diego
- Research Site - Sepulveda
Alabama
- Research Site - Jasper
- Research Site - Mobile
Arkansas
- Research Site - Fort Smith
- Research Site - Little Rock
Arizona
- Research Site - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00419744 record still lists
NCT00419744 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, below the 1,740-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Budesonide/formoterol (SYMBICORT) pMDI is the first listed.
NCT00419744 names 20 study sites across 4 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00419744 about?
NCT00419744 is a clinical study titled "A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD". The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
What is the current status of trial NCT00419744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2007-01. Estimated completion is 2009-08.
What conditions does trial NCT00419744 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT00419744?
The interventions under investigation include: Budesonide/formoterol (SYMBICORT) pMDI (DRUG), Formoterol Turbuhaler (DRUG).
Who is sponsoring clinical trial NCT00419744?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419744 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00419744's enrollment target sits among peer trials
1,200 11th of 86 higher than 76 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia